FDA Clears Multi-Patient CT Injection System from Bayer
Facilitating optimal use of contrast, the Medrad Centargo CT Injection System reportedly combines user-friendly features with workflow efficiency for high-volume CT departments.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the Medrad Centargo CT Injection System, which enables contrast administration for multiple patients undergoing computed tomography (CT) exams.
Featuring a pre-assembled Day Set and a snap-in patient line that auto-primes upon insertion, the Medrad Centargo CT Injection System allows contrast set-up for multiple patients to be completed in less than two minutes, according to Bayer, the manufacturer of the Medrad Centargo CT Injection System.
The newly FDA-cleared Medrad Centargo CT Injection System reportedly allows contrast set-up for multiple patients to be completed in less than two minutes. (Photo courtesy of Bayer.)
For demanding CT protocols, Bayer said the system also has a Dual Flow feature that allows simultaneous administration of contrast and saline, which is facilitated by the Medrad Centargo CT Injection System’s piston-based technology.
The combination of automated documentation software and the system’s integrated barcode reader enables simplified access to contrast and injection details to help streamline reporting.
“We know radiologists today are facing a continuously increasing workload, and the automation, integration and mobility of the Medrad® Centargo CT Injection System helps radiology staff do more with less, allowing them more time to focus on their patients,” noted Sven Schmidt, the head of Region Americas Radiology at Bayer.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
